Autologous peripheral blood hematopoietic stem cell transplantation in the treatment of three cases of severe pemphigus
10.3760/cma.j.issn.0412-4030.2012.06.019
- VernacularTitle:自体外周血造血干细胞移植治疗重症天疱疮三例
- Author:
Kang ZENG
;
Lu YAN
;
Jing SUN
;
Fanyi MENG
;
Ledong SUN
;
Qifa LIU
;
Dan XU
;
Qian WANG
;
Kuan LAI
;
Zaigao ZHOU
- Publication Type:Journal Article
- From:
Chinese Journal of Dermatology
2012;45(6):435-437
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo explore the clinical efficacy and safety of autologous peripheral blood stem cell transplantation(APBSCT) in the treatment of pemphigus.MethodsTotally,3 patients with pemphigus vulgaris who responsed poorly to 6-month treatment with glucocorticoids or immunosuppressants or experienced aggrevation of disease and developed treatment-related complications,received APBSCT and were followed up for more than 5 years.There were 1 male and 2 females with an average age of 27.3(21-39) years.The mobilization program included cyclophosphamide (CTX) 4 g/m2,recombinant human granulocyte colonystimulating factors(G-CSF) and Rituximab 375 mg/m2,and the preconditioning regimen included intravenous CTX (50 mg/kg per day on days -6,-5,-4,-3),antithymocyte globulin at 2.5 mg/kg per day(on days -3,-2,-1 and 0) and Rituximab (600 mg/d on days 0 and 7).ResultsAll the 3.patients were successfully engrafted.The mean time for peripheral reconstruction:white blood cells 13.3 days (from day 11 to 16),platelet 16.3 days (from day 16 to 17).Monitoring of immunity indices and related antibodies showed no abnormality and the immune system was well reconstructed.No serious complications occurred during the follow up,and the patients' quality of life was obviously improved.ConclusionAPBSCT may be an effective and safe option for the treatment of pemphigus.
